Health TrialsbyHealthPanel

Pulmonary Hypertension and RV Dysfunction in Myeloproliferative Neoplasms

ConditionsMyeloproliferative NeoplasmRight Ventricular DysfunctionPulmonary Hypertension
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssiut University

About this trial

This cross-sectional study aims to determine the prevalence of pulmonary hypertension and right ventricular dysfunction in patients with myeloproliferative neoplasms and to identify associated clinical and hematologic factors.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

- Age 18 years or older

Confirmed diagnosis of myeloproliferative neoplasm (polycythemia vera, essential thrombocythemia, or primary myelofibrosis)

Stable clinical condition

Written informed consent

Disqualifiers

- Significant left-sided valvular heart disease

Congenital heart disease

COPD or interstitial lung disease causing pulmonary hypertension

Poor echocardiographic window

Trial population

Adult patients with confirmed myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, or primary myelofibrosis) attending the Hematology Unit and Critical Care Department at Assiut University Hospital.

Trial design

Design model

Case-only

Time perspective

Cross-sectional

Treatments tested in this trial

Not listed

Trial groups

145 Participants
are grouped into 1 trial group
Group A: Single cohort: Patients with myeloproliferative neoplasms

Trial outcomes

Primary outcomes

1

Prevalence of Pulmonary Hypertension in MPN Patients

PASP measured by echocardiography using TR velocity. Pulmonary hypertension defined as PASP greater than 35 mmHg or TR velocity greater than 2.8 m/s. Prevalence will be calculated.

Time frame
Baseline

Secondary outcomes

1

Prevalence of right ventricular dysfunction

Proportion of patients with right ventricular dysfunction defined by TAPSE \<17 mm, RV fractional area change \<35%, or tissue Doppler S' \<9.5 cm/s

Time frame
Baseline
2

Pulmonary artery systolic pressure

Mean estimated pulmonary artery systolic pressure (mmHg) measured by echocardiography

Time frame
Baseline
3

Tricuspid annular plane systolic excursion (TAPSE)

Mean TAPSE value (mm) measured by echocardiography.

Time frame
Baseline
4

Right ventricular fractional area change

Mean right ventricular fractional area change (%) measured by echocardiography.

Time frame
Baseline

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assiut University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: